VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Amgen Inc. vs Bio-Rad Laboratories, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Amgen Inc.
AMGN · Nasdaq Stock Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Bio-Rad Laboratories, Inc.
BIO · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bio-Rad Laboratories, Inc.'s moat claims, evidence, and risks.
View BIO analysisComparison highlights
- Moat score gap: Amgen Inc. leads (70 / 100 vs 61 / 100 for Bio-Rad Laboratories, Inc.).
- Segment focus: Amgen Inc. has 3 segments (80.1% in Core Innovative Medicines); Bio-Rad Laboratories, Inc. has 2 segments (59.9% in Clinical Diagnostics).
- Primary market structure: Competitive vs Oligopoly. Pricing power: Moderate vs Moderate.
- Moat breadth: Amgen Inc. has 5 moat types across 3 domains; Bio-Rad Laboratories, Inc. has 6 across 3.
Primary market context
Amgen Inc.
Core Innovative Medicines
Branded biopharmaceutical therapies for common diseases (bone health, inflammation, oncology, cardiovascular and other specialty areas)
Global
Payers, providers, and pharmacies
Drug developer/manufacturer
80.1%
Bio-Rad Laboratories, Inc.
Clinical Diagnostics
In vitro diagnostics test systems, reagents/test kits, informatics, and clinical laboratory quality controls
Global
Hospital laboratories; diagnostic reference laboratories; transfusion laboratories; physician office laboratories
IVD OEM / installed-base consumables supplier (systems + kits + controls)
59.9%
Side-by-side metrics
Moat coverage
Shared moat types
Amgen Inc. strengths
Bio-Rad Laboratories, Inc. strengths
Segment mix
Amgen Inc. segments
Full profile >Core Innovative Medicines
Competitive
Rare Disease Portfolio (Horizon + others)
Quasi-Monopoly
Biosimilars
Oligopoly
Bio-Rad Laboratories, Inc. segments
Full profile >Life Science
Competitive
Clinical Diagnostics
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.